An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE)

RATIONALE: High circulating galectin-3 is associated with poor outcomes in patients with coronavirus disease (COVID-19). We hypothesized that GB0139, a potent inhaled thiodigalactoside galectin-3 inhibitor with antiinflammatory and antifibrotic actions, would be safely and effectively delivered in C...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaughan, Erin E., Quinn, Tom M., Mills, Andrew, Bruce, Annya M., Antonelli, Jean, MacKinnon, Alison C., Aslanis, Vassilios, Li, Feng, O’Connor, Richard, Boz, Cecilia, Mills, Ross, Emanuel, Philip, Burgess, Matthew, Rinaldi, Giulia, Valanciute, Asta, Mills, Bethany, Scholefield, Emma, Hardisty, Gareth, Findlay, Emily Gwyer, Parker, Richard A., Norrie, John, Dear, James W., Akram, Ahsan R., Koch, Oliver, Templeton, Kate, Dockrell, David H., Walsh, Timothy S., Partridge, Stephen, Humphries, Duncan, Wang-Jairaj, Jie, Slack, Robert J., Schambye, Hans, Phung, De, Gravelle, Lise, Lindmark, Bertil, Shankar-Hari, Manu, Hirani, Nikhil, Sethi, Tariq, Dhaliwal, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893334/
https://www.ncbi.nlm.nih.gov/pubmed/35972987
http://dx.doi.org/10.1164/rccm.202203-0477OC

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893334/
https://www.ncbi.nlm.nih.gov/pubmed/35972987
http://dx.doi.org/10.1164/rccm.202203-0477OC

Ejemplares similares